S&P 500 slips on report Fed’s Waller leading race to replace Powell; tech shines
Investing.com - Axsome Therapeutics Inc (NASDAQ: AXSM) reported second quarter EPS of $-1.67, $0.36 worse than the analyst estimate of $-1.31. Revenue for the quarter came in at $87.2M versus the consensus estimate of $86.66M.
Axsome Therapeutics Inc's stock price closed at $84.42. It is up 11.55% in the last 3 months and up 14.61% in the last 12 months.
Axsome Therapeutics Inc saw 0 positive EPS revisions and 11 negative EPS revisions in the last 90 days. See Axsome Therapeutics Inc's stock price’s past reactions to earnings here.
According to InvestingPro, Axsome Therapeutics Inc's Financial Health score is "fair performance".
Check out Axsome Therapeutics Inc's recent earnings performance, and Axsome Therapeutics Inc's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar